A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5044
Abstract: Regorafenib is one of several FDA‐approved cancer therapies targeting multiple tyrosine kinases. However, there are few subtype‐specific data regarding kinase inhibitor activity in sarcomas. We report results of a single arm, phase II trial of… read more here.
Keywords: trial regorafenib; trial; phase trial; regorafenib patients ... See more keywords
Effectiveness and Safety of Reduced and Standard Initial Doses of Regorafenib in Patients With Metastatic Colorectal Cancer: A Multicenter Retrospective Study in Taiwan
Sign Up to like & getrecommendations! Published in 2025 at "Pharmacoepidemiology and Drug Safety"
DOI: 10.1002/pds.70221
Abstract: This study aims to compare the effectiveness and safety of standard and reduced initial doses of regorafenib in patients with metastatic colorectal cancer (mCRC). read more here.
Keywords: effectiveness safety; regorafenib patients; doses regorafenib; patients metastatic ... See more keywords